Key result
Operation linked to ~44% lower mortality risk versus no treatment in primary angiosarcoma.
Why the study?
Angiosarcoma is a rare malignant vascular tumor with management and outcomes that are not well-described.
Does operation with additional chemo or radiation therapy improve survival compared to operation alone in patients with angiosarcoma?
Population
5,135 patients with angiosarcoma in the SEER database between 1975 and 2016
Comparison
Operation with chemo or radiation therapy vs operation alone vs no operation
Design
Registry-based retrospective cohort study using inverse probability treatment weighting
Follow-up
5 years
Authors
Loading...
Multimodal therapy may improve long-term angiosarcoma survival after early risks; leaves open optimal selection and timing without prospective trials.
Cohort (n=5,135)
Yes
Does operation with additional chemo or radiation therapy improve survival compared to operation alone in patients with angiosarcoma?
Hazard Ratio: 0.56 (95% CI 0.47–0.66)
p-value: p=<0.001
Multimodal therapy in the form of neoadjuvant or adjuvant chemo/radiation therapy offers significant long-term survival benefits over operation alone for patients with angiosarcoma.
Yan et al. (2022) conducted a cohort in Angiosarcoma (n=5,135). Operation vs. No treatment was evaluated on Overall survival (HR 0.56, 95% CI 0.47-0.66, p=<0.001). Operation was associated with a 44% reduction in mortality risk compared to no treatment (HR 0.56) in patients with primary angiosarcoma, with an overall 5-year survival of 26.7%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: